1-3 of 3
David Valdecanas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer

Free
Xiyou Liu, Manish Kumar, Liangpeng Yang, David P. Molkentine, David Valdecanas, Shiying Yu, Raymond E. Meyn, John V. Heymach, Heath D. Skinner
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (3): 600–607.
https://doi.org/10.1158/1078-0432.CCR-17-1573
Published: 31 January 2018
View articletitled, BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer
Open the PDF for BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

130-nm Albumin–Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain

Available to Purchase
Nicole Wiedenmann, David Valdecanas, Nancy Hunter, Stephen Hyde, Thomas A. Buchholz, Luka Milas, Kathryn A. Mason
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1868–1874.
https://doi.org/10.1158/1078-0432.CCR-06-2534
Published: 15 March 2007
View articletitled, 130-nm Albumin–Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain
Open the PDF for 130-nm Albumin–Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain in another window
Journal Articles

Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy

Available to Purchase
Kathryn A. Mason, Hisanori Ariga, Robert Neal, David Valdecanas, Nancy Hunter, Arthur M. Krieg, John K. Whisnant, Luka Milas
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (1): 361–369.
https://doi.org/10.1158/1078-0432.361.11.1
Published: 21 January 2005
View articletitled, Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy
Open the PDF for Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy in another window